DNADX® analyzes tumor tissue or plasma circulating tumor DNA to identify clinically relevant biomarkers. The test reports SNVs and CNAs of breast cancer driver genes and provides CNA-based subtyping*
*Based on REVEAL GENOMICS’ proprietary machine-learning model, Xia, Y., et al. Nat Commun (2019). doi: 10.1038/s41467-019-13588-2
Prat,A., et al. Nat Commun (2023). doi: 10.1038/s41467-023-36801-9 .
DNADX® is a groundbreaking test designed for patients facing advanced breast cancer.
Our proprietary software, used for diagnostic testing, examines the DNA from tumor tissue or circulating tumor DNA (ctDNA) in the blood.
By analyzing distinctive gene patterns, we uncover crucial details that go beyond single gene alterations, offering valuable insights to shape personalized and targeted treatment plans.